nVerses Capital’s Prime Medicine PRME Stock Holding History

nVerses Capital’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,500	Closed	-$18K	–	1327
2024 Q2	$18K	Buy	+3,500	New	+$21.2K	0.01%	816

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

nVerses Capital's PRME Position: Q3 2024 in Review

nVerses Capital sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 3,500 shares — an estimated $18K sold.

nVerses Capital first reported a position in PRME in Q2 2024 and held it in 1 quarter. The position peaked at $18K in Q2 2024. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

nVerses Capital reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 3,500 Prime Medicine shares in Q3 2024, an estimated $18K.
nVerses Capital first reported a position in Prime Medicine in Q2 2024 and held it in 1 quarter.
nVerses Capital's Prime Medicine position peaked at $18K in Q2 2024.
116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.